1.Functions of Siglecs in Allergic Inflammation.
Pediatric Allergy and Respiratory Disease 2006;16(3):197-205
Siglecs are sialic acid binding Ig-like lectins, subset of the immunoglobulin superfamily. They are characterized by a homologous N-terminal V-set Ig-like domain and C2 set Ig-like domains. N-terminal domains have sialic acid binding activity. In humans, 11 Siglecs have been described sialoadhesin(Siglec-1), CD22(Siglec-2), CD33(Siglec-3), MAG(Siglec-4), more recently described CD33-related Siglecs(Siglec 5-11). Siglecs express most signal via immunoreceptor tyrosine-based inhibition motif(ITIM) cytoplasmic domains. The cytoplasmic tails of all Siglecs except sialoadhesin have one or more tyrosine residues within potential signaling motifs. Inhibitory function of other Siglecs such as Siglec-7 or Siglec-9 was shown in RBL-2H3 cells. Co-crosslinking of Siglec-7 or Siglec-9 and Fc epsilon R1 substantially reduced the serotonin release of RBL-7 and RBL-9 cells. Siglec-8 is expressed on human eosinophils, mast cells and basophils. Siglec-8 has two tyrosine motifs, a proximal motif and a distal motif. They have some inhibitory functions in immune system. We have observed that Siglec-8 is able to inhibit the IgE receptor-mediated beta-hexosaminidase release of RBL-2H3 cells following co-crosslinking. Co-crosslinking of Siglec-8 and Fc epsilon R1 reduced the hexosaminidase release of RBL-2H3 cells. These results show that Siglec-8 is as potent as Siglec-7 and Siglec-9 in delivering inhibitory signals to RBL-2H3 cells. Siglec-8 should be a new member of the inhibitory receptor superfamily and the membrane-proximal ITIM is essential for the inhibitory function of Siglec-8 molecules. Although these molecules present specific marker for the allergic cell types, more work is needed to understand the signaling mechanism and the role in various disease processes.
Basophils
;
beta-N-Acetylhexosaminidases
;
Cytoplasm
;
Eosinophils
;
Hexosaminidases
;
Humans
;
Immune System
;
Immunoglobulin E
;
Immunoglobulins
;
Inflammation*
;
Lectins
;
Mast Cells
;
N-Acetylneuraminic Acid
;
Serotonin
;
Sialic Acid Binding Ig-like Lectin 1
;
Sialic Acid Binding Immunoglobulin-like Lectins*
;
Tyrosine
3.Research progress on the role and clinical application of Siglecs in tumor immunity.
Hui CHEN ; Jialin LU ; Danru WANG ; Lihao SUI ; Sheng XU
Chinese Journal of Cellular and Molecular Immunology 2023;39(12):1125-1131
Lectins are proteins responsible for recognizing the signals of sugar molecules in the body. Sialic acid-binding immunoglobulin-like lectins (Siglecs) regulate the innate and adaptive immune responses in the tumor microenvironment by recognizing the glycan structure containing sialic acid and mediating downstream signals through immune receptor tyrosine inhibitory motifs. In recent years, a variety of tumor treatment strategies targeting the sialic acid-Siglecs axis have been introduced, including sialoglycoprotein-mediated drug delivery and antibody mediated inhibition of Siglecs from recognizing tumor surface ligands. In the future, by combining with glycoprotein nanotherapy, antibody therapy and gene therapy, Siglecs can be used to accurately locate tumor targets and release the anti-tumor immunity, so as to achieve the purpose of effective cure of tumors.
Sialic Acid Binding Immunoglobulin-like Lectins/metabolism*
;
N-Acetylneuraminic Acid
;
Immunoglobulins/metabolism*
;
Receptors, Immunologic
;
Ligands
4.Potential Targeting of Siglecs, Mast Cell Inhibitory Receptors, in Interstitial Cystitis.
Chang Shin PARK ; Bruce S BOCHNER
International Neurourology Journal 2011;15(2):61-63
Mast cell increases and activation are detected in the chronic inflammatory bladder disease interstitial cystitis (IC), and their proinflammatory mediators are felt to contribute to regional pelvic pain and inflammatory pathophysiology. The immunoreceptor tyrosine-based inhibition motif-containing sialic acid-binding immunoglobulin-like lectins (Siglecs) expressed in mast cells could be evaluated as in vivo signaling regulators capable of inhibiting IC-related mast cell activation.
Cystitis, Interstitial
;
Lectins
;
Mast Cells
;
Pelvic Pain
;
Sialic Acid Binding Immunoglobulin-like Lectins
;
Urinary Bladder
;
Urinary Bladder Diseases
5.Effect of downregulation the expression of HDAC1 on cells differentiation of HL-60 cells.
Shan-Liang LU ; Yi-Qun HUANG ; Xu-Dong MA
Acta Pharmaceutica Sinica 2013;48(5):668-674
This study is to investigate the effect of downregulation histone deacetylases 1 (HDAC1) gene by the technology of RNA interference on the differentiation of HL-60 cells line. The optimal segment targeting HDAC1 gene was designed and transfected into HL-60 cells by Lipofectamine 2000. The HDAC1 mRNA and protein level were detected by RT-PCR and Western blotting. The morphologic change of HL-60 cells was detected by an optical microscope with Wright-Giemsa. Cell differentiation was tested by NBT reduction assay. Expression of CD13, CD33 and CD14 was measured by flow cytometry. The results indicated that HDAC1 mRNA and protein were markedly suppressed by the siRNA targeting HDAC1 in a concentration-dependent manner. HDAC1 siRNA promoted cell differentiation. HL-60 cells became more mature in morphology after transfected to HDAC1 siRNA at a concentration of 30-60 nmol x L(-1) for 24 h. NBT reduction ability of HDAC1 siRNA with 30 nmol x L(-1) was 0.31 +/- 0.09, compared with negative control (0.20 +/- 0.02) (t = -3.1, P < 0.01), and with 60 nmol x L(-1) was 0.25 +/- 0.02 in comparison with negative control (0.21 +/- 0.04) (t = -2.12, P < 0.05). But it has no change in HDAC1 siRNA > or = 120 nmol x L(-1). After transfection with 60 nmol x L(-1) HDAC1 siRNA to HL-60 cells, the expression of CD13 was (96.50 +/- 0.70)% in compared to siRNA-NC (3.39 +/- 0.68) % (t = 164.9, P < 0.000 5), CD33 was (66.73 +/- 0.50) % in compared to siRNA-NC (96.80 +/- 1.70) % (t = 43.4, P < 0.000 5). CD14 was (0.53 +/- 0.00) % by comparison with siRNA-NC (0.49 +/- 0.02) % (t = -0.97, P > 0.1). HDAC1 siRNA promoted cell differentiation in indicated concentration. HDAC1 might be one of the targets of gene therapy for leukemia.
CD13 Antigens
;
metabolism
;
Cell Differentiation
;
Down-Regulation
;
HL-60 Cells
;
Histone Deacetylase 1
;
genetics
;
metabolism
;
Humans
;
Lipopolysaccharide Receptors
;
metabolism
;
RNA Interference
;
RNA, Messenger
;
metabolism
;
RNA, Small Interfering
;
genetics
;
Sialic Acid Binding Ig-like Lectin 3
;
metabolism
;
Transfection
6.Specific regulator of eosinophil apoptosis: Siglec-8-new hope for bronchial asthma treatment.
Chinese Medical Journal 2012;125(11):2048-2052
OBJECTIVEIt is known that Siglec-8 is selectively expressed on human eosinophils at a high level and mediates eosinophil apoptosis when crosslinked with its antibody. The aim of our review is to elucidate the molecular and biological characteristic of Siglec-8 and then discuss the function and possible mechanisms of Siglec-8 in eosinophils. Thereby, we will expand our understanding to the regulation of eosinophil apoptosis, and provide important clues to the treatment of asthma and other hyper-eosinophilic diseases.
DATA SOURCESMost articles were identified by searching of PubMed online resources using the key term Siglecs.
STUDY SELECTIONMainly original milestone articles and critical reviews written by major pioneer investigators in the field were selected.
RESULTSSiglec-8 is selectively expressed on human eosinophil and can specifically induce eosinophil apoptosis.
CONCLUSIONThe restricted expression of Siglec-8 on human eosinophil and the rapid progress in understanding its role as cell signaling and activation of death receptors have made it an attractive target for treatment of asthma and other hyper-eosinophilic diseases.
Apoptosis ; genetics ; physiology ; Asthma ; metabolism ; therapy ; Eosinophils ; cytology ; metabolism ; Humans ; Sialic Acid Binding Immunoglobulin-like Lectins ; metabolism
7.Siglec-15 promotes progression of clear renal cell carcinoma.
Wen-Bo YANG ; Cai-Peng QIN ; Yi-Qing DU ; Song-Chen HAN ; Tao XU
Chinese Medical Journal 2021;134(21):2635-2637
8.Characteristics of 4 specific target antigens in adult acute lymphoblastic leukemia.
Zhong-Kun LIN ; Run ZHANG ; Zheng GE ; Juan LIU ; Yu-Jie WU ; Xing GUO ; Chun QIAO ; Hai-Rong QIU ; Jian-Yong LI
Journal of Experimental Hematology 2013;21(2):289-295
This study was aimed to investigate clinical and prognostic significances of 4 target antigens (CD19, CD20, CD22 and CD33) for antibody-based immunotherapy and to evaluate the applications of these antibody-based target therapy to adult acute lymphoblastic leukemia (ALL). The immunophenotype of 220 adult patients with ALL were analyzed by four-color flow Cytometry, and cytogenetic and molecular parameters were detected by conventional cytogenetics, fluorescence in situ hybridization, real-time quantitative PCR, nested PCR and DNA sequencing. The results showed that CD19 positive (CD19(+)) cases were more in female (46.4% vs. 23.4%, P = 0.006), elderly patients aged > 60 years (14.4% vs. 2.1%, P = 0.022), CD33(+) co-expression cases (47.8% vs. 12.0%, P = 0.001) and genetic high-risk group (55.8% vs. 20.8%, P = 0.002) compared with CD19 negative (CD19(-)) cases; CD20(+) cases had lower co-expression of CD13 than CD20(-) cases (31.6% vs.67.1%, P = 0.000) and no significant prognostic indications for CD20(+) was observed; CD22(+) cases had higher relapse rate at 12-month than CD22(-) cases (93.9% vs.57.1%, P = 0.041) in B-ALL patients; CD33(+) cases had higher incidence of Ph(+) than CD33(-) cases (43.5% vs.19.4%, P = 0.007) and significantly correlated with Ph(+) (r = 0.261, P = 0.006). It is concluded that elucidation of the characteristics of the target antigens (CD19, CD20, CD22, CD33) used for antibody-based immunotherapy will help hematologists making the correct decision whether and when to use these antibody-based target therapies.
Adolescent
;
Adult
;
Aged
;
Antigens, CD19
;
immunology
;
Antigens, CD20
;
immunology
;
Child
;
Female
;
Humans
;
Immunophenotyping
;
Male
;
Middle Aged
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
genetics
;
immunology
;
Sialic Acid Binding Ig-like Lectin 2
;
immunology
;
Sialic Acid Binding Ig-like Lectin 3
;
immunology
;
Young Adult
9.Effect of Anti-Siglec-F Antibody and Reactive Oxygen Species Blocking on Histamine Release in Urinary Bladder of Ovalbumin-Treated Mice.
Bo Hwa CHOI ; Gwoan Youb CHOO ; Ju Hee KANG ; Choong Yeol LEE ; Chang Shin PARK
International Neurourology Journal 2012;16(3):122-125
PURPOSE: Sialic acid-binding Ig-like lectin (Siglec) is an immune inhibitory receptor that plays a role in the negative regulation of the activation of immune cells. This study aimed to evaluate the effects of anti-Siglec-F on plasma and urinary histamine levels in ovalbumin (OVA)-challenged urinary bladder in mice. METHODS: Thirty BALB/c mice were used. In group I (control group, n=5), mice were sensitized with OVA and challenged with saline. In group II (OVA challenge group, n=5), OVA was used for intraperitoneal sensitization and intravesical challenge. The challenged mice in group III (control immunoglobulin G [IgG] group, n=5) and those in group IV (anti-Siglec-F group, n=5) were intraperitoneally pretreated with rabbit control IgG or anti-Siglec-F antibody, respectively. In groups V (N-acetylcysteine [NAC] in OVA challenge group, n=5) and VI (control NAC only, n=5), mice were pretreated with NAC. RESULTS: Urinary histamine concentrations were significantly higher 7 days after intravesical OVA challenge (P<0.01), whereas plasma histamine levels were not. Pretreatment with anti-Siglec-F antibody significantly prevented the increase in urinary histamine release (P<0.05), whereas pretreatment with the IgG antibody control did not. Also, pretreatment of the OVA challenge group with NAC did not affect the histamine concentration in either urine or plasma. CONCLUSIONS: Systemic anti-Siglec-F treatment showed anti-allergic effects at least on local histamine release, particularly in the lower urinary bladder.
Animals
;
Histamine
;
Histamine Release
;
Immunoglobulin G
;
Mice
;
Ovalbumin
;
Ovum
;
Plasma
;
Reactive Oxygen Species
;
Sialic Acid Binding Immunoglobulin-like Lectins
;
Urinary Bladder
10.Sialic acid-binding immunoglobulin-like lectin 9 as a potential therapeutic target for chronic obstructive pulmonary disease.
Zi CHEN ; Shuang-Lan XU ; Lin-Yang GE ; Jin ZHU ; Tao ZHENG ; Zhou ZHU ; Linfu ZHOU
Chinese Medical Journal 2021;134(7):757-764
Chronic obstructive pulmonary disease (COPD) has become the third-leading cause of death worldwide, which is a severe economic burden to the healthcare system. Chronic bronchitis is the most common condition that contributes to COPD, both locally and systemically. Neutrophilic inflammation predominates in the COPD airway wall and lumen. Logically, repression of neutrophilia is an essential fashion to COPD treatment. However, currently available anti-neutrophilic therapies provide little benefit in COPD patients and may have serious side effects. Thus, there is an urgent need to explore an effective and safe anti-neutrophilic approach that might delay progression of the disease. Sialic acid-binding immunoglobulin-like lectin (Siglec)-9 is a member of the Siglec cell surface immunoglobulin family. It is noteworthy that Siglec-9 is highly expressed on human neutrophils and monocytes. Ligation of Siglec-9 by chemical compounds or synthetic ligands induced apoptosis and autophagic-like cell death in human neutrophils. Furthermore, administration of antibody to Siglec-E, mouse functional ortholog of Siglec-9, restrained recruitment and activation of neutrophils in mouse models of airway inflammation in vivo. Given the critical role that neutrophils play in chronic bronchitis and emphysema, targeting Siglec-9 could be beneficial for the treatment of COPD, asthma, fibrosis, and related chronic inflammatory lung diseases.
Animals
;
Asthma
;
Humans
;
Lung
;
Mice
;
N-Acetylneuraminic Acid
;
Neutrophils
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
;
Sialic Acid Binding Immunoglobulin-like Lectins